{"disease":{"id":"recurrent-cancer","name":"recurrent cancer"},"drugs":{"marketed":[{"drug_id":"nivolumab","indication_name":"Unresectable, advanced or recurrent gastric cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Opdivo","generic_name":"nivolumab","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Programmed cell death protein 1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"9200","mechanism":"Opdivo works by blocking the PD-1 receptor on immune cells, allowing them to attack cancer cells."},{"drug_id":"ipilimumab","indication_name":"Unresectable advanced or recurrent esophageal cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Yervoy","generic_name":"ipilimumab","company_name":"Bristol-Myers Squibb","drug_phase":"discontinued","molecular_target":"Cytotoxic T-lymphocyte protein 4","drug_class":"CTLA-4-directed Blocking Antibody","quality_score":0,"revenue":"2900","mechanism":"Yervoy blocks a protein called CTLA-4, which normally helps to turn off the immune system, allowing it to attack cancer cells."},{"drug_id":"dostarlimab","indication_name":"Recurrent or advanced endometrial cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Jemperli","generic_name":"DOSTARLIMAB","company_name":"GSK","drug_phase":"marketed","molecular_target":"PD-1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"800","mechanism":"Dostarlimab-gxly binds to PD-1 and blocks its interaction with PD-L1 and PD-L2, enhancing the immune response against tumors."},{"drug_id":"tisotumab-vedotin","indication_name":"Recurrent or metastatic cervical cancer with disease progression on or after chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tivdak","generic_name":"tisotumab-vedotin","company_name":"SEAGEN","drug_phase":"marketed","molecular_target":"Tissue factor","drug_class":"Antibody-drug conjugate","quality_score":10,"revenue":"147","mechanism":"Tisotumab vedotin is a tissue factor (TF)-directed antibody drug conjugate that targets and disrupts microtubule networks in cancer cells."},{"drug_id":"tisotumab","indication_name":"recurrent or metastatic cervical cancer with disease progression on or after chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tivdak","generic_name":"TISOTUMAB","company_name":"Seagen","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":64,"revenue":"147","mechanism":"Tivdak works by binding to a specific target on cancer cells, triggering an immune response to destroy the cancer."},{"drug_id":"tivdak","indication_name":"Treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tisotumab Vedotin","generic_name":"tivdak","company_name":"SEAGEN","drug_phase":"marketed","molecular_target":"Tissue factor","drug_class":"Antibody-Drug Conjugate (ADC)","quality_score":10,"revenue":"147","mechanism":""},{"drug_id":"avutometinib","indication_name":"KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avmapki Fakzynja Co-Pack","generic_name":"AVUTOMETINIB","company_name":"Verastem Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":53,"revenue":null,"mechanism":"Avmapki Fakzynja Co-Pack works by blocking a protein that helps cancer cells grow."},{"drug_id":"avutometinib","indication_name":"KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avmapki Fakzynja Co-Pack","generic_name":"AVUTOMETINIB","company_name":"Verastem Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":53,"revenue":null,"mechanism":"Avmapki Fakzynja Co-Pack works by blocking a protein that helps cancer cells grow."},{"drug_id":"rucaparib","indication_name":"Maintenance treatment of BRCA-mutated recurrent ovarian cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rubraca","generic_name":"RUCAPARIB","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PARP-1, PARP-2, PARP-3","drug_class":"","quality_score":50,"revenue":null,"mechanism":"Rucaparib inhibits PARP enzymes, causing DNA damage and cancer cell death, especially in cells with BRCA1/2 deficiencies."},{"drug_id":"pembrolizuma","indication_name":"Advanced or recurrent cervical cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pembrolizuma","company_name":"Memorial Sloan Kettering Cancer Center","drug_phase":"marketed","molecular_target":"Programmed cell death protein 1","drug_class":"","quality_score":14,"revenue":null,"mechanism":null},{"drug_id":"dostarlimab-gxly","indication_name":"Recurrent or advanced endometrial cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"JEMPERLI","generic_name":"DOSTARLIMAB-GXLY","company_name":"GLAXOSMITHKLINE","drug_phase":"marketed","molecular_target":"PD-1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":"Dostarlimab-gxly blocks PD-1 receptor interaction with PD-L1 and PD-L2, enhancing anti-tumor immune response."},{"drug_id":"yervoy","indication_name":"Unresectable advanced or recurrent esophageal cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Yervoy","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Cytotoxic T-lymphocyte protein 4","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"dacomitinib-hydrate","indication_name":"EGFR mutation-positive, unresectable or recurrent non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"dacomitinib hydrate","generic_name":"dacomitinib-hydrate","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"Cyclin-G-associated kinase, Receptor-interacting serine/threonine-protein kinase 2, Receptor-interacting serine/threonine-protein kinase 3","drug_class":"The usual adult starting dosage for oral use is 45mg of dacomitinib hydrate once daily. The dose sho","quality_score":null,"revenue":null,"mechanism":"The usual adult starting dosage for oral use is 45mg of dacomitinib hydrate once daily. The dose sho"},{"drug_id":"vizimpro","indication_name":"EGFR mutation-positive, unresectable or recurrent non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vizimpro","generic_name":"Dacomitinib","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Cyclin-G-associated kinase, Receptor-interacting serine/threonine-protein kinase 2, Receptor-interacting serine/threonine-protein kinase 3","drug_class":"Tyrosine kinase inhibitor (TKI); Pan-HER inhibitor","quality_score":75,"revenue":null,"mechanism":"Irreversible pan-HER kinase inhibitor targeting EGFR, HER2, HER4, and EGFR-activating mutations."},{"drug_id":"dacomitinib","indication_name":"EGFR mutation-positive, unresectable or recurrent non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vizimpro","generic_name":"dacomitinib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Epidermal growth factor receptor","drug_class":"","quality_score":70,"revenue":null,"mechanism":"Vizimpro works by blocking the EGFR tyrosine kinase, a protein that helps cancer cells grow and survive."},{"drug_id":"bevacizumab-maly","indication_name":"Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"ALYMSYS","generic_name":"BEVACIZUMAB-MALY","company_name":"AMNEAL PHARMS LLC","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"chembl-chembl1789844","indication_name":"Metastatic or Recurrent Non-Small Cell Lung Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"IPILIMUMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"CTLA-4-directed Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"bevacizumab-maly","indication_name":"Persistent, Recurrent, or Metastatic Cervical Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"ALYMSYS","generic_name":"BEVACIZUMAB-MALY","company_name":"AMNEAL PHARMS LLC","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"chembl-chembl3301587","indication_name":"Advanced or Recurrent Endometrial Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DURVALUMAB","company_name":"","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Programmed Death Ligand-1 Blocker [EPC]","quality_score":10,"revenue":null,"mechanism":"Durvalumab binds to PD-L1, blocking its interaction with PD-1 and CD80, enhancing T-cell activation and reducing tumor size."},{"drug_id":"brigatinib","indication_name":"Advanced/recurrent anaplasticlymphoma kinase (ALK)-positive non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Alunbrig","generic_name":"brigatinib","company_name":"Takeda","drug_phase":"marketed","molecular_target":"ALK tyrosine kinase receptor","drug_class":"Kinase Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Alunbrig works by blocking the activity of the ALK tyrosine kinase receptor, which is involved in the growth and spread of cancer cells."}],"pipeline":[],"offLabel":[],"totalMarketed":20,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05384002","title":"An AI Platform Integrating Imaging Data and Models, Supporting Precision Care Through Prostate Cancer's Continuum","phase":"","overall_status":"COMPLETED","enrollment_count":14000,"lead_sponsor_name":"Fondazione del Piemonte per l'Oncologia","has_results":false},{"nct_id":"NCT05200195","title":"Deep Learning Model for the Prediction of Post-LT HCC Recurrence","phase":"","overall_status":"COMPLETED","enrollment_count":4026,"lead_sponsor_name":"European Hepatocellular Cancer Liver Transplant Group","has_results":false},{"nct_id":"NCT04979780","title":"Observational Studies in Cancer Associated Thrombosis for Rivaroxaban - United States Cohort","phase":"","overall_status":"COMPLETED","enrollment_count":3708,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT01275677","title":"Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":3270,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03461341","title":"European iNvestigation of SUrveillance After Resection for Esophageal Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":3000,"lead_sponsor_name":"St. James's Hospital, Ireland","has_results":false},{"nct_id":"NCT04326088","title":"Postoperative Complication After Free Flap Reconstruction for Head and Neck Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":2004,"lead_sponsor_name":"Chang Gung Memorial Hospital","has_results":false},{"nct_id":"NCT04596865","title":"Recurrence After Whipple's (RAW) Study","phase":"","overall_status":"COMPLETED","enrollment_count":1484,"lead_sponsor_name":"University Hospital Plymouth NHS Trust","has_results":false},{"nct_id":"NCT01953588","title":"Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1473,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":false},{"nct_id":"NCT00063999","title":"Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1381,"lead_sponsor_name":"GOG Foundation","has_results":true},{"nct_id":"NCT01949337","title":"Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":1311,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":true},{"nct_id":"NCT06168032","title":"COVID-19 Vaccine Effectiveness Against Recurrent Infection Among Lung Cancer Patients and Biomarker Research","phase":"NA","overall_status":"RECRUITING","enrollment_count":1224,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT07030686","title":"Association Between Exercise, Patient-Reported Outcomes, and Clinical Events in Adult Cancer Survivors","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT05794906","title":"A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":985,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT01463891","title":"Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S)","phase":"","overall_status":"COMPLETED","enrollment_count":963,"lead_sponsor_name":"Eisai Co., Ltd.","has_results":false},{"nct_id":"NCT04050215","title":"68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":937,"lead_sponsor_name":"Jonsson Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT03564340","title":"Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":890,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT02358031","title":"A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":882,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT05838066","title":"Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":880,"lead_sponsor_name":"Shanghai JMT-Bio Inc.","has_results":false},{"nct_id":"NCT05352178","title":"Metastasis-directed Therapy for Oligorecurrent Prostate Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":873,"lead_sponsor_name":"Universitaire Ziekenhuizen KU Leuven","has_results":false},{"nct_id":"NCT05633602","title":"Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":838,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":false},{"nct_id":"NCT04423211","title":"Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":804,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":false},{"nct_id":"NCT06088134","title":"Contrast-enhanced CT-based Deep Learning Model for Preoperative Prediction of Disease-free Survival (DFS) in Localized Clear Cell Renal Cell Carcinoma (ccRCC)","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"Mingzhao Xiao","has_results":false},{"nct_id":"NCT07494864","title":"Effects of Microbiological and Immunological Factors on the Lower Urinary Tract","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"University of Zurich","has_results":false},{"nct_id":"NCT00785291","title":"Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":799,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06155422","title":"A Prospective Real-world Study of Cadonilimab in Patients With Recurrent or Metastatic Cervical Cancer","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":670,"lead_sponsor_name":"Gang Chen (101199)","has_results":false},{"nct_id":"NCT04092283","title":"Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":660,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT00954174","title":"Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":637,"lead_sponsor_name":"GOG Foundation","has_results":true},{"nct_id":"NCT03257267","title":"Study of Cemiplimab in Adults With Cervical Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":608,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":true},{"nct_id":"NCT01473784","title":"Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck","phase":"NA","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Ohio State University Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT07004582","title":"Lab Research Using Mini-tumors to Study Prostate Cancer Treatments","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":600,"lead_sponsor_name":"Maastricht Radiation Oncology","has_results":false},{"nct_id":"NCT01365169","title":"Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients\"","phase":"NA","overall_status":"RECRUITING","enrollment_count":590,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03933826","title":"CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":570,"lead_sponsor_name":"University of Washington","has_results":true},{"nct_id":"NCT03315364","title":"Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":549,"lead_sponsor_name":"Daehwa Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT02041533","title":"An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":541,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT06378866","title":"Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":532,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT06114420","title":"Surgical Treatment and Molecular Marker Exploration of Locally Recurrent Colorectal Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT03418961","title":"S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":491,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":false},{"nct_id":"NCT02065687","title":"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":469,"lead_sponsor_name":"Gynecologic Oncology Group","has_results":true},{"nct_id":"NCT04623775","title":"A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":468,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT04787744","title":"Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":464,"lead_sponsor_name":"VA Office of Research and Development","has_results":false},{"nct_id":"NCT03786094","title":"Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":432,"lead_sponsor_name":"Spexis AG","has_results":true},{"nct_id":"NCT05063552","title":"Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":430,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05798819","title":"A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":424,"lead_sponsor_name":"Guangzhou Gloria Biosciences Co., Ltd.","has_results":false},{"nct_id":"NCT03398655","title":"A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":408,"lead_sponsor_name":"Vascular Biogenics Ltd. operating as VBL Therapeutics","has_results":false},{"nct_id":"NCT00588770","title":"Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":403,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05855811","title":"PREventing Second Cancers With DOSTARlimab","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Centre Leon Berard","has_results":false},{"nct_id":"NCT07406542","title":"A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":400,"lead_sponsor_name":"CSPC Megalith Biopharmaceutical Co.,Ltd.","has_results":false},{"nct_id":"NCT03174912","title":"In the Prediction of Recurrence and Progression of NMIBC; EORTC or CUETO or Both?","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":400,"lead_sponsor_name":"Ankara Training and Research Hospital","has_results":false},{"nct_id":"NCT04026230","title":"Impact of Atorvastatin on Prostate Cancer Progression During ADT","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":400,"lead_sponsor_name":"Tampere University Hospital","has_results":false},{"nct_id":"NCT03507595","title":"Evaluation of the Metastasis and Recurrence of Prostate Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":400,"lead_sponsor_name":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}